This statistic depicts the market share of Neupogen (filgrastim) and its U.S. biosimilars from 2015 to 2024. In 2015, some ** percent of filgrastim sales were attributable to Neupogen. However, as of Q4 2024, just ** percent of filgrastim sales were attributable to Neupogen.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Samsung Bioepis. (February 5, 2019). Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/
Samsung Bioepis. "Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024." Chart. February 5, 2019. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/
Samsung Bioepis. (2019). Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/
Samsung Bioepis. "Filgrastim Market Share of Neupogen and Its U.S. Biosimilar Competitors between 2015 and 2024." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 5 Feb 2019, /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/
Samsung Bioepis, Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024 ÌÇÐÄÆƽâ°æ, /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/ (last visited July 29, 2026)
Filgrastim market share of Neupogen and its U.S. biosimilar competitors between 2015 and 2024 [Graph], Samsung Bioepis, February 5, 2019. [Online]. Available: /statistics/869873/percentage-neupogen-sales-loss-to-biosimilars/
